This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David R. Fett, MD; Clifford A. Silverman; Marc O. Yoshizumi, MD

Arch Ophthalmol. 1984;102(3):435-438.

Abstract
• Moxalactam disodium is a new third-generation semisynthetic, broad-spectrum, cephalosporin-like antibiotic for parenteral administration. Topical, subconjunctival, and intravenous administration provide poor concentration in the vitreous. To determine its toxicity in intra-vitreal administration, we injected comparative doses directly into the vitreous cavity of 21 rabbits. With doses of 1.25 mg or less there was no toxic damage to the retina. With a dose of 2.5 mg, early degeneration of photoreceptors was seen after three months. With higher doses (5 and 10 mg) there were major histopathologic and electroretinographic changes. These results suggest the feasibility of employing moxalactam in the treatment of acute, severe, fulminant bacterial endophthalmitis.

Author Affiliations
From the Retina Division, Jules Stein Eye Institute, UCLA School of Medicine.

Footnotes
Accepted for publication May 3, 1983.

Reprint requests to Jules Stein Eye Institute, UCLA School of Medicine, Los Angeles, CA 90024 (Dr Yoshizumi).

Eli Lilly provided the moxalactam.

Suzanne Gardner, PharmD, and Dean Bok, PhD, acted as consultants, Richard Evans prepared the photographs, and Deidre Martin advised and assisted in the electrophysiologic testing.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravitreal Moxalactam
Leeds and Peyman
Arch Ophthalmol 1984;102:1267-1268.
ABSTRACT